- Fee assured
- Awaiting verification
- Movement disorders
After obtaining her medical degree (University of London, 1993) Michele was awarded an Action Research Training Fellowship and PhD in an imaging study of Parkinson’s cortical/striatal brain function. In 2005 Michele set up a neurology consultant-led clinical Parkinson’s disease and movement disorders service in Oxford and Milton Keynes. Michele is National Institute for Health Research (NIHR) Parkinson’s Thames Valley Research Director, and member of the NIHR Parkinson’s Clinical Study/Portfolio Management Groups. In 2014 she became chair of the Research engagement sub-committee of the UK Parkinson's excellence network. She is co-Principal Investigator and Clinical Theme Leader of the Oxford Parkinson’s Disease Centre (OPDC), established in 2009 with the £5 million Parkinson’s UK-funded Monument Discovery Award to understand the early pathological pathways in Parkinson’s (http://opdc.medsci.ox.ac.uk).
Areas of interest
Botulinum therapy for dystonia and migraine; Parkinson's disease; Movement disorders, Dystonia, Atypical parkinsonism including PSP, MSA and CBD; General neurology
Current NHS consultant posts held
01/11/05-06/08/13 Neurology Consultant, Milton Keynes Hospital NHS Foundation Trust/ Oxford University Hospitals NHS Trust
07/08/13-Current Associate Professor, Nuffield Department of Clinical Neurosciences, University of Oxford and Consultant Neurologist, Oxford University Hospitals NHS Trust
Michele is co-Principal Investigator of the Oxford Parkinson’s Disease Centre (OPDC), established in 2009 with the £10.7 million Parkinson’s UK-funded Monument Discovery Award to understand the early pathological pathways in Parkinson’s (http://opdc.medsci.ox.ac.uk). Research interests include the use of longitudinal clinical cohorts and brain imaging to develop biomarkers for the early diagnosis/prognostication of Parkinson’s
Gardening, running and spending time with her husband and children outdoors
Parkinson’s UK Monument Discovery Award “Understanding the early pathological pathways to Parkinson’s disease”. PI Dr R Wade-Martins, Co-PI Dr M Hu, £5 million, Sep 2009; £5.8 million Sep 2014.
”Virtual, physiological and computational neuromuscular models for the predictive treatment of Parkinson’s Disease- NoTremor”. EU project Award, co-I M Hu. €632,800,Nov 2013.
(Additional) Languages spoken
Selected recent publications:
Rolinski MR, Zokaei N, Baig F, Giehl K, Quinnell T, Zaiwalla Z, Mackay CE, Husain M, Hu MTM. Visual short-term memory deficits in REM sleep behavior disorder mirror those in Parkinson’s disease. Brain 2016, 139:47-53.
Muhammed K Manohar S, Tofaris G, Lennox G, Bogdanovic M, Hu M, Husain M. Reward sensitivity deficits underlie apathy in Parkinson’s disease. JNNP 2015, in press.
Griffanti L, Rolinski M, Szewczyk-Krolikowski K, Menke RA, Filippini N, Zamboni G, Jenkinson M, Hu MT, Mackay CE. Challenges in the reproducibility of clinical studies with resting state fMRI: an example in early Parkinson’s disease. NeuroImage 2016,124(PtA):704-13
Lerche S, Liepelt-Scarfone I, Alves G et al. Methods in Neuroepidemiology Characterization of European longitudinal cohort studies in Parkinson’s disease - Report of the JPND working group BioLoC-PD. Neuroepidemiology 2015, 45(4):282-97
Baig F, Lawton M, Rolinski M, Ruffmann C, Nithi K, Evetts SG, Fernandes HR, Ben-Shlomo Y, Hu MT. Delineating Non-Motor Symptoms in Early Parkinson’s Disease and First Degree Relatives. Mov Disord 2015, 30 (131759-66
Lawton M, Baig F, Rolinski M, Ruffman C, Nithi K, May MT, Ben-Shlomo Y and Hu MTM. Parkinson’s disease subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery cohort. J Parkinson’s Disease, 2015;5:269-279.
Antoniades CAA, Demeyere N, Kennard C, Humphreys GW and Hu MT. Antisaccades and executive dysfunction in early drug–naive Parkinson’s disease; the Discovery Study. Mov Disord, 2015, 30(6):843-7.
Szewczyk-Krolikowski K , Menke RAL, Filippini N, Zamboni G, Talbot K, PhD, Hu MT and Mackay CE (joint senior authors). Functional connectivity in the Basal Ganglia network differentiates PD patients from Controls. Neurology 2014, PMID: 24920856.
Hu MT, Szewczyk-Krolikowski K, Tomlinson P, Nithi K, Murray C, Talbot K, Ebmeier K, Mackay C, Ben-Shlomo Y. Predictors of cognitive impairment in an early stage Parkinson’s disease cohort. Mov Disord, 2014, PMID: 24395708.
Rolinski M, Ben-Shlomo Y, Szewczyk-Krolikowski K, Tomlinson P, Nithi K, Murray C, Talbot K, Hu MT. REM sleep behavior disorder is associated with worse non-motor characteristics in an early Parkinson’s disease cohort. JNNP 2014, PMID: 24187013.
Courses offered to GPs
Parkinson's and Movement Disorders Seminars
- MBBS King's College Hospital Medical and Dental School 1993
- MRCP Royal College of Physicians, London 1996
- FRCP Royal College of Physicians, London 2009
- PhD University of London 2001
- CCT Neurology Joint Royal Colleges of Physicians Training Board, London 2005
Reference number 4027225
Professional bodies (positions held - last 3 yrs)
- Fellow Royal College of Physicians, London 2009
- Member Association of British Neurologists 2000
- Member Movement Disorders Society 1997
- Member British Movement Disorders Group 2005
- Member General Medical Council 1993
Details of entry to specialist register
- CCT Neurology, 2005
Affiliations / memberships
- Nuffield Health The Manor Hospital, OX3 7RP
- 09:00 - 13:00
- 01865 231295
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
Dr Michele Hu